PMA device
Biocor and Biocor Supra Valves
Abbott Medical · Heart-Valve, Non-Allograft Tissue (LWR, Class III) · First FDA decision May 6, 2008, newest Dec 17, 2010Aortic stenosisMitral regurgitationTricuspid regurgitation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
1
Naming "Biocor"
MAUDE reports
0
Brand "Biocor", since 2015
PubMed studies
107
Mentioning "Biocor"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Biocor and Biocor Supra Valves
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 2 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Biocor", any status and sponsor, newest update first.
Abbott Medical DevicesPublic (ABT)
NCT00636987 · 297 participants · Start Apr 2007 · Primary completion Oct 2015
Device: Biocor and Biocor Supra valves · For: Aortic Valve Insufficiency; Aortic Valve Regurgitation; Aortic Valve Stenosis and 5 more
Sites: La Jolla, California; Los Angeles, California; Evansville, Indiana · 17 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Biocor", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LWR
17,256 reports: 871 malfunction, 15,439 injury, 934 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Biocor"[tiab]. The summary above synthesizes these.
- Biocor No- React stentless aortic valve--short-term results.
Von Oppell UO, Stemmet F, Levetan B, et al. · Cardiovasc J S Afr · 2001Research Support, Non-U.S. Gov't
- Long-term follow-up of stentless prosthesis.
Sansone F, Dato GM, Zingarelli E, et al. · J Cardiol · 2014
- The extended Biocor stentless aortic bioprosthesis. Early clinical experience.
Dellgren G, Eriksson M, Brodin LA, et al. · Scand Cardiovasc J · 1999Research Support, Non-U.S. Gov't
- Comparative clinical study on the efficacy of biocor plus compared with simvastatin for the management of hypercholesterolemia.
Sheikh ZS, Usmanghani K, Nazar H, et al. · Pak J Pharm Sci · 2015
- Results of Biocor stentless valve replacement for infective endocarditis of the native aortic valve.
Santini F, Bertolini P, Vecchi B, et al. · Am J Cardiol · 1998
- Long-term results with the Biocor-SJM stentless porcine aortic bioprosthesis.
Vrandecic M, Fantini FA, Filho BG, et al. · J Heart Valve Dis · 2002
- Mid-term follow-up in patients with Biocor porcine bioprostheses.
Bottio T, Rizzoli G, Gerosa G, et al. · Cardiovasc Surg · 2002
- Contemporary evidence of long-term follow-up of the EpicTM prosthesis after mitral valve replacement.
Acuña Pais B, Otero Lozano D, Sisinni Ganly CM, et al. · J Cardiovasc Thorac Res · 2025
- Net pressure gradients in aortic prosthetic valves can be estimated by Doppler.
Bech-Hanssen O, Gjertsson P, Houltz E, et al. · J Am Soc Echocardiogr · 2003Comparative Study, Research Support, Non-U.S. Gov't
- Eleven years' experience with the Biocor stentless aortic bioprosthesis: clinical and hemodynamic follow-up with long-term relative survival rate.
Dellgren G, Eriksson MJ, Brodin LA, et al. · Eur J Cardiothorac Surg · 2002Evaluation Study, Research Support, Non-U.S. Gov't
- Twenty-Seven-Year Experience With the St. Jude Medical Biocor Bioprosthesis in the Aortic Position.
Guenzinger R, Fiegl K, Wottke M, et al. · Ann Thorac Surg · 2015
- Transcatheter tricuspid valve-in-valve implantation with bioprosthetic balloon expandable valve.
Haji-Zeinali AM, Etesamifard N, Mohammadi Z, et al. · Gen Thorac Cardiovasc Surg · 2022
Other devices of this type
Also filed under product code LWR.
- Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2022
- St. Jude Medical Biocor and Biocor Supra ValvesAbbott Medical · PMA 2012
- INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2026
- Mitroflow Aortic Pericardial Heart ValveCorcym Canada Corp · PMA 2019
- TRIFORMIS RESILIA Tricuspid ValveEdwards Lifesciences, LLC · PMA 2026
- Perceval Sutureless Heart Valve, Perceval Plus Sutureless Heart ValveCorcym S.r.l. · PMA 2025
- Sjm Biocor Valve / Sjm Biocor Supra ValveAbbott Medical · PMA 2016
- Ats 3F Aortic Bioprosthesis Model 1000Medtronic, Inc. · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.